Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling

Fig. 4

DAPA treatment inhibits the activation of the TGF-β1/Smad pathway in rats with continuous Ang II infusion. A Immunohistochemical analysis for the effect of DAPA on Ang II-induced expression of TGF-β1in myocardial tissue. Values are presented as means ± SD (n = 6 rats per group). *P < 0.05 relative to CTL group. †P < 0.05 relative to Ang II group.Scale bars = 100 μm; B inhibition of Ang II infusion -induced activation of TGF-β1/Smad pathway. The relative ratio of TGF-β1 and Smad7 over β-actin was determined by densitometric analysis respectively. Also, the ratio of phosphor-Smad2/Smad2 and phosphor-Smad3/Smad3 was calculated based on densitometric analysis. Values are means ± SD (n = 6). *P < 0.05 relative to CTL group. †P < 0.05 relative to Ang II group

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840